EV 404053075

75 US

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Request
For
Continued Examination (RCE)
Continued Examination (RCE)  Transmittal O P E

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

itta	ro	ŧ	_	E	3
2	JUN	3	0	2004	51 33
TE .	ر ام			· at	

a concolon of information anicoon a	iopidio a valia Olvidi control manibor.		
Application Number	10/016,146		
Filing Date	December 10, 2001		
First Named Inventor	Jay Cunningham		
Art Unit	1614		
Examiner Name	Phyllis G. Spivack		
Attorney Docket Number	3078/4 (6794-000094/COC)		

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 C.F.R. 1.114  Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).							
a. Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.							
i. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ii. Other							
	_	on Disclosure Statement ( tion for extension of time; ret	•				
2. Miscellaneous							
a. Suspension of action on the above-identified application is requested under 37 C.F.R. 1.103(c) for a period ofmonths. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. 1.17(i) required)							
b. Other  3. Fees The RCE fee under 37 C.F.R. 1.17(e) is required by 37 C.F.	.R. 1.114 when t	the RCE is filed.					
a.   The Director is hereby authorized to charge any deficiencies or additional fees, or credit any overpayments, to  Deposit Account No.08-0750							
i. RCE fee required under 37 C.F.R. 1.17(e) ii. Extension of time fee (37 C.F.R. 1.136 and 1.17) iii. Other							
b. Check in the amount of \$ 1720.00 enclosed							
<ul> <li>c. Payment by credit card (Form PTO-2038 enclosed)</li> <li>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</li> </ul>							
SIGNATURE OF APPLICANT, ATTO	RNEY, OR AG	SENT REQUIRED					
Name (Print /Type) James E. Davis	Registration	No. (Attorney/Agent)	47,516				
Signature \(\sum_{\infty} \in \tau_{\infty}\)	Date	June 30, 2004					
() CERTIFICATE OF MAILING	OR TRANSM	IISSION					
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below:							
Name (Print /Type) James E. Davis							
Signature \( \sum_{\infty} \sum_{\infty} \sum_{\infty}	Date June 30, 2004						

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## EV 404053075 US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Jay Cunningham et al.

Application No:

10/016,146

Filed:

December 10, 2001

Title:

 $\alpha_{v}\beta_{3}$  Integrin antagonists in combination with

CHEMOTHERAPEUTIC AGENTS

Group Art Unit:

1614

Confirmation No:

7806

Examiner:

Phyllis G. Spivak

Attorney Ref:

3078/US/04

HDP Ref:

6794-000094/US/COC

## AMENDMENT C AND REQUEST FOR CONTINUED EXAMINATION

June 30, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## Dear Sir/Madam:

In response to the final Office action mailed December 31, 2003, please enter the amendments and remarks set forth below.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 12 of this paper.